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Abstract
Patients with metastatic renal cell carcinoma (mRCC) have better overall survival when treated with nivolumab, a cancer immunotherapy that targets the immune checkpoint inhibitor programmed cell death 1 (PD-1), rather than everolimus (a chemical inhibitor of mTOR and immunosuppressant). Poor-risk mRCC patients treated with nivolumab seemed to experience the greatest overall survival benefit, compared to patients with favorable or intermediate-risk, in an analysis of the CheckMate-025 trial subgroup of the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk groups. Here we explore whether tumor mutational load and RNA expression of specific immune parameters could be segregated by prognostic MSKCC risk strata and explain the survival seen in the poor-risk group. We queried whole exome transcriptome data in RCC patients (n = 54) included in The Cancer Genome Atlas that ultimately developed metastatic disease or were diagnosed with metastatic disease at presentation and did not receive immune checkpoint inhibitors. Nonsynonymous mutational load did not differ significantly by MSKCC risk group, nor was the expression of cytolytic genesgranzyme A and perforin -or selected immune checkpoint molecules different across MSKCC risk groups. In conclusion, this analysis found that mutational load and expression of markers of an active tumor microenvironment did not correlate with MSKCC risk prognostic classification in mRCC. Immunohistochemical staining of tumor PD-1 ligand (PD-L1), the main biomarker correlate on the trial, showed that patients with high PD-L1 positivity tended to experience poorer survival whether treated with nivolumab or everolimus, suggesting PD-L1 staining has more prognostic than predictive value in mRCC and therefore this marker should not be used as a marker of treatment benefit in RCC. In this investigation, we sought to explore whether tumor mutational load and RNA expression of specific immune parameters segregated by prognostic MSKCC risk strata associated with greater likelihood of clinical benefit, namely OS, from nivolumab in the poor-risk group observed in CheckMate 025. We queried whole exome transcriptome data in RCC patients included in The Cancer Genome Atlas (TCGA) that ultimately developed metastatic disease or were diagnosed with metastatic disease at presentation (mRCC; n = 54, out of a total of 390 total cases) (8) . This cohort of patients did not receive immune checkpoint inhibitors. This study is exploratory in nature and no predefined statistical assumptions were considered.
The median nonsynonymous mutational load in the aggregate mRCC cohort was 54 mutations/sample (range: 1-99) ( Fig.   1A ). We repeated the analysis classifying our 54 patients according to the more contemporary International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk criteria (9) and again mutational loads did not differ across different risk strata (P = 0.39; Kruskal-Wallis chi-squared).
Although RCC has lower mutational rates compared to other tumors in which immune checkpoint blockade has been successful, such as melanoma, bladder, and non-small-cell lung cancer (7, (9) (10) (11) , its cytolytic activity is one of the highest of all cancer types (12), suggesting that an immunoreactive tumor microenvironment may be involved in mediating response to immunotherapies. Whole transcriptome data for the same set of 54 TCGA patients, revealed no differences in expression of cytolytic genes -granzyme A (GZMA) and perforin (PRF1) -or in selected immune checkpoint molecules (PD-1, PD-L1, PD-L2, CTLA-4) across MSKCC risk groups (P > 0.05 for all; Kruskal-Wallis chisquared) (Fig. 1B-C) .
It is also possible that the clinical observation of nivolumab providing superior benefit to poor-risk patients is due to a lower activity of everolimus in these patients. This speculation is not supported by the historical perspective in which temsirolimus -another sirolimus analog -showed a preferential benefit in patients with multiple poor prognostic features (13) .
Intriguing data shows that anti-PD-L1 therapy may be associated with superior responses in tumors with Fuhrman grade 4 and/or sarcomatoid features (14) . To avoid this potentially cofounding factor, we obtained Fuhrman grade information in our series 
and did not find an association between patients with low, intermediate, and high grades with MSKCC risk categories (P = 0.17).
In conclusion, this analysis in 54 clinically annotated whole-exome-and wholetranscriptome-sequenced RCC samples found that mutational load and expression of markers of an active tumor microenvironment, does not correlate with MSKCC risk prognostic classification in mRCC and, therefore cannot explain the superior benefit of nivolumab over everolimus in the poor-risk subgroup. We cannot exclude the fact that a real difference could not be detected because of the smaller size of our cohort. Other hypotheses to explore include the role of specific neoantigens in mediating response to mRCC: although mRCC may not be highly mutated on average, the presentation of a small number of immunogenic tumor-specific peptides may be sufficient to engender strong antitumor responses following release of immunosuppression using a cancer immunotherapy. Similarly, more complex interactions of tumors and the immune microenvironment may inform the subtype-specific response associations observed clinically that may be revealed through T-cell receptor sequencing (15) . Given the large number of immunotherapies in clinical trials or preclinical development for mRCC, identifying patients most likely to benefit -or not -from these new treatments is a clinical priority for the future of cancer precision medicine. Biomarker-based studies with ample baseline and on-therapy tissue collection may lead to new biologic insights 
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